In a recent study, Maciocia et al. develop a novel T cell receptor beta (TCRB) constant C1-chain-directed cellular immunotherapy for the treatment of T cell malignancies.
This is a preview of subscription content, log in via an institution to check access.
References
Pishko, A. & Nasta, S.D. Transl. Cancer Res. 6, 93–103 (2017).
Ramos, C.A. et al. J. Clin. Invest. 126, 2588–2596 (2016).
Toyonaga, B., Yoshikai, Y., Vadasz, V., Chin, B. & Mak, T.W. Proc. Natl. Acad. Sci. USA 82, 8624–8628 (1985).
Schwartz, R.H. Annu. Rev. Immunol. 3, 237–261 (1985).
Warner, K. et al. Curr. Hematol. Malig. Rep. 8, 163–172 (2013).
Nikolich-Zugich, J., Slifka, M.K. & Messaoudi, I. Nat. Rev. Immunol. 4, 123–132 (2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Palomero, T., Ferrando, A. Targeted cellular immunotherapy for T cell malignancies. Nat Med 23, 1402–1403 (2017). https://doi.org/10.1038/nm.4458
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4458
- Springer Nature America, Inc.
This article is cited by
-
Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products
Pharmaceutical Research (2021)
-
Pregnant rats exposed to low-level methylmercury exhibit cerebellar synaptic and neuritic remodeling during the perinatal period
Archives of Toxicology (2020)